Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
4.020
+0.350 (9.54%)
At close: Aug 13, 2025, 4:00 PM
4.050
+0.030 (0.75%)
After-hours: Aug 13, 2025, 6:11 PM EDT
Company Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
It also develops TGF-β, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Inventiva S.A.
| Country | France |
| Founded | 2011 |
| IPO Date | Jul 10, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 118 |
| CEO | Frederic Cren |
Contact Details
Address: 50 rue de Dijon Daix, 21121 France | |
| Phone | 33 3 80 44 75 00 |
| Website | inventivapharma.com |
Stock Details
| Ticker Symbol | IVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $14.40 |
| CIK Code | 0001756594 |
| CUSIP Number | 46124U107 |
| ISIN Number | US46124U1079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pierre Broqua Ph.D. | Co-Founder, Chief Scientific Officer and Deputy Chief Executive Officer |
| Frederic Cren | Co-Founder, Chief Executive Officer and Director |
| Dr. Martine Zimmermann Pharm.D. | Executive Vice President of Regulatory Affairs and Quality Assurance and Director |
| Jean Volatier | Deputy GM and Chief Financial Officer |
| Alice Roudot-Ketelers Pharm.D. | Chief Operating Officer |
| Eric Duranson L.L.M. | General Counsel |
| Nathalie Harroy | Head of Human Resources |
| Dr. Kristina Meyer Ph.D. | Executive Vice President and Business Development and Alliance Management |
| Dr. Michael Cooreman M.D., Ph.D. | Chief Medical Officer |
| Pascaline Clerc Ph.D. | Executive Vice President of Strategy and Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 31, 2025 | SCHEDULE 13G/A | Filing |
| Jul 29, 2025 | 6-K | Report of foreign issuer |
| Jul 9, 2025 | 6-K | Report of foreign issuer |
| Jul 7, 2025 | 6-K | Report of foreign issuer |
| Jun 20, 2025 | SCHEDULE 13G | Filing |
| May 23, 2025 | 6-K | Report of foreign issuer |
| May 23, 2025 | 6-K | Report of foreign issuer |
| May 22, 2025 | 6-K | Report of foreign issuer |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 9, 2025 | SCHEDULE 13D/A | Filing |